Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). CorMedix announced financial results for the quarter ended September 30, 2026.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CorMedix announced financial results for the quarter ended September 30, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
- DefenCath revenue $17.2M, including a $5.0M favorable sales-allowance estimate change, signaling underlying pricing sensitivity
- Net loss $14.7M and adjusted EBITDA $3.1M, sharply below prior-year adjusted EBITDA $71.9M
- FY 2026 revenue guidance maintained at $325M-$345M, while adjusted EBITDA guidance narrowed to $130M-$140M
- Heron asset acquisition expected in Q1 2027, with projected 2027 revenue contribution of $125M-$150M and up to $150M term-loan capacity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.